Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

被引：0
|
作者：
Barba, Pere [1 ]
Lanar, Sally [2 ]
Liu, Fei Fei [3 ]
Eliason, Laurie [3 ]
Askew, Kshawna [4 ]
Devlen, Jennifer [5 ]
Furustrand, Ulrika [3 ]
Kostic, Ana [3 ]
机构：
[1] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Barcelona, Spain
[2] ICON Plc, Lyon, France
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] ICON Plc, Winston Salem, NC USA
[5] ICON Plc, Raleigh, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178858
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
    Van Le, Hoa
    Braun, Kim Van Naarden
    Nowakowski, Grzegorz S.
    Sermer, David
    Radford, John
    Townsend, William
    Ghesquieres, Herve
    Menne, Tobias
    Porpaczy, Edit
    Fox, Christopher P.
    Schusterbauer, Claudia
    Liu, Fei Fei
    Yue, Lihua
    De Benedetti, Marc
    Hasskarl, Jens
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 573 - 585
  • [42] Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael
    Arnason, Jon E.
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Kostic, Ana
    Kim, Yeonhee
    Ogasawara, Ken
    Dehner, Christine
    Siddiqi, Tanya
    BLOOD, 2021, 138
  • [43] Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Zhou, Daobin
    Wang, Zhao
    Zhang, Mingzhi
    Wu, Jianqiu
    Liu, Hui
    Wang, Chris
    Ma, Laura
    Yang, Su
    Zhou, Zisong
    Qin, Yun
    Song, Yuqin
    Zhu, Jun
    CYTOTHERAPY, 2023, 25 (05) : 521 - 529
  • [44] LENALIDOMIDE LONG-TERM NEUROTOXICITY: NEUROPHYSIOLOGICAL FOLLOW-UP STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA
    Dalla Torre, C.
    Cacciavillani, M.
    Campagnolo, M.
    Lucchetta, M.
    Bemo, T.
    De March, E.
    Zambello, R.
    Briani, C.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 122 - 122
  • [45] The role of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma - a long-term follow-up single center experience
    Roerden, M.
    Soekler, M.
    Kanz, L.
    Bethge, W.
    Vogel, W.
    Walz, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 163 - 163
  • [46] Pivotal Safety and Efficacy Results From TRANSCEND NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphomas
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 8 - 10
  • [47] Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
    Zinzani, P. L.
    Vose, J. M.
    Czuczman, M. S.
    Reeder, C. B.
    Haioun, C.
    Polikoff, J.
    Tilly, H.
    Zhang, L.
    Prandi, K.
    Li, J.
    Witzig, T. E.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2892 - 2897
  • [48] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Linhares, Yuliya
    Freytes, Cesar
    Cherry, Mohamad
    Bachier, Carlos
    Maris, Michael
    Hoda, Daanish
    Varela, Juan C.
    Bellomo, Courtney
    Cross, Scott
    Essell, James
    Fanning, Suzanne
    Terebelo, Howard
    Yimer, Habte
    Courtright, Jay
    Sharman, Jeff P.
    Kostic, Ana
    Vedal, Min
    Ogasawara, Ken
    Avilion, Ariel
    Espinola, Ricardo
    Yuan, Brenda
    Mattar, Bassam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S514 - S515
  • [50] LONG-TERM FOLLOW-UP RESULTS OF AN ONGOING PIVOTAL STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
    Smith, S.
    Chen, R.
    Gopal, A.
    Ansell, S.
    Rosenblatt, J.
    Savage, K.
    Connors, J.
    Engert, A.
    Larsen, E.
    Sievers, E.
    Younes, A.
    HAEMATOLOGICA, 2012, 97 : 456 - 456
12345